Immuno1
Pioneering a New Era in Prostate Cancer Treatment
At ImmunoPDT, research and development are the foundation of our mission to redefine cancer care without compromise. Over a decade of rigorous science and more than $50 million invested in technology development have led to a breakthrough therapy that is safe, effective, and immune-activating.
Our work bridges oncology, immunotherapy, and photodynamic science — transforming how prostate cancer is treated and opening new frontiers for other hard-to-treat cancers.
HOW OUR TECHNOLOGY WORKS
Our proprietary semi-synthetic, chlorophyll-derived photosensitizer "Immuno1" selectively enters cancer cells via sugar transport pathways. Once activated by light, it:
- Destroys tumor tissue precisely without harming healthy cells.
- Triggers a systemic immune response, enabling the body to mop up residual or resistant cancer cells.
- Provides a walk-in, walk-out procedure — painless, anesthesia-free, and clinic-ready.
This dual mechanism — targeted cell destruction plus immune activation — makes ImmunoPDT a world-first immunotherapy for prostate cancer
our commitment
We are committed to painless, precise, immune-activating, and globally scalable therapies. By combining deep science, robust clinical evidence, and world-class partnerships, ImmunoPDT is positioned to transform prostate cancer from a life-threatening disease into a manageable condition